Drug Profile
Research programme: anti-HLA monoclonal antibodies - Wakunaga Pharmaceutical
Alternative Names: Anti-HLA-B61 monoclonal antibody - Wakunaga Pharmaceutical; Anti-HLA-Bw4 monoclonal antibody - Wakunaga PharmaceuticalLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Wakunaga Pharmaceutical
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in Japan (Parenteral)
- 09 Dec 2017 Preclinical trials in Haematological malignancies in Japan prior to 9/12/2017 (Parenteral)
- 09 Dec 2017 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 59th Annual Meeting and Exposition of the American Society of Hematology